Postrelapse survival in XXXX of the extremities: prognostic factors for long-term survival.

@entity1 @entity632 @entity75 @entity900 @entity421 @entity1260 @entity1499 @entity1349
PURPOSE: To identify factors that influence @entity1349 ( @entity1349 ) in @entity1 with nonmetastatic @entity421 . @entity1 AND METHODS: One hundred sixty-two @entity1 with recurrent @entity421 were retrospectively reviewed. The first-line treatment included surgery of the @entity75 and chemotherapy with @entity1499 , @entity632 , @entity900 , and @entity1260 . RESULTS: The projected 5-year @entity1349 rate was 28%. @entity1 who had complete surgery of recurrence had a 5-year @entity1349 of 39%, whereas for those who did not have complete surgery, @entity1349 was 0% at 3 years (P <.0001). In the latter group, @entity1349 was not influenced by site of recurrence and relapse-free interval (RFI), although it was influenced (P =.006) by the use of second-line chemotherapy ( @entity1349 , 53% at 12 months for @entity1 who received chemotherapy v 12% for those who did not). In @entity1 who had complete surgery, @entity1349 was influenced by site of relapse (5-year @entity1349 , lung 44%, other 19%; P <.06), RFI (5-year @entity1349 at < or = 24 months, 20%; at > 24 months, 60%; P <.0001), and number of lung metastases (5-year @entity1349 , two or fewer nodules, 59%; more than two nodules, 14%; P <.0001) but not by the use of a second-line chemotherapy treatment. CONCLUSION: RFI, site of metastases, and number of pulmonary nodules are the main prognostic factors for @entity1349 in @entity421 . Complete surgery of recurrence is pivotal in the strategy of treatment. @entity1 with unresectable recurrence benefit from second-line chemotherapy, whereas our data do not support a generalized use of chemotherapy after complete surgery of first recurrence.
